Multivariate regression model for each severity stage with results for SNPs rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> (data of other SNPs is shown in S3 Table).

<p>Multivariate regression model for each severity stage with results for SNPs rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> (data of other SNPs is shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156778#pone.0156778.s003" target="_blank">S3 Table</a>).</p

Area under the curve (AUC) of risk models in different AMD severity stages.

<p>Area under the curve (AUC) of risk models in different AMD severity stages.</p

Grading results.

<p>Grading results.</p

Demographics.

<p>Demographics.</p

Univariate regression analysis for SNPs rs10490924 in ARMS2 and rs1061170 in CFH in patients with unilateral nAMD and different severity stages of the fellow-eye.

<p>Univariate regression analysis for SNPs rs10490924 in ARMS2 and rs1061170 in CFH in patients with unilateral nAMD and different severity stages of the fellow-eye.</p

Distribution of single nucleotide polymorphisms rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> and trend test of AMD severity stages (data of other SNPs is shown in S1 Table).

<p>Distribution of single nucleotide polymorphisms rs10490924 in <i>ARMS2</i> and rs1061170 in <i>CFH</i> and trend test of AMD severity stages (data of other SNPs is shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0156778#pone.0156778.s001" target="_blank">S1 Table</a>).</p

Additional file 1: of Prophylactic intravitreal 5-fluorouracil and heparin to prevent proliferative vitreoretinopathy in high-risk patients with retinal detachment: study protocol for a randomized controlled trial

SPIRIT 2013 Checklist. (DOC 101 kb

Results of the multiple logistic regressions after automatic selection, approach 1, early detectable parameters and approach 2, later detectable parameters.

<p>Results of the multiple logistic regressions after automatic selection, approach 1, early detectable parameters and approach 2, later detectable parameters.</p

CONSORT flow diagram of the WestGem-study.

<p>CONSORT flow diagram of the WestGem-study.</p

Baseline characteristics of the studied patient group (N = 129).

<p>Data is presented as mean ± SD unless otherwise indicated.</p